{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=CpG+1018%C2%AE",
    "query": {
      "intervention": "CpG 1018®"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 4,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-23T06:49:53.395Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05506969",
      "title": "Trial of the Immunogenicity, Safety, and Tolerability of rF1V Vaccine With CpG 1018® Adjuvant Compared With rF1V Vaccine in Adults 18 to 55 Years of Age",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Plague, Pneumonic",
        "Plague",
        "Vaccine-Preventable Diseases"
      ],
      "interventions": [
        {
          "name": "rF1V-1018",
          "type": "BIOLOGICAL"
        },
        {
          "name": "rF1V vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Dynavax Technologies Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 200,
      "start_date": "2022-08-09",
      "completion_date": "2024-04-26",
      "has_results": true,
      "last_update_posted_date": "2025-07-29",
      "last_synced_at": "2026-09-23T06:49:53.395Z",
      "location_count": 6,
      "location_summary": "Huntsville, Alabama • San Diego, California • Melbourne, Florida + 3 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Melbourne",
          "state": "Florida"
        },
        {
          "city": "Peoria",
          "state": "Illinois"
        },
        {
          "city": "Rockville",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05506969"
    },
    {
      "nct_id": "NCT06334393",
      "title": "Phase 1 Trial to Assess the Safety and Immunogenicity of an Inactivated, Adjuvanted Whole Zika Virus Vaccine Candidate (VLA1601) in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Zika",
        "Zika Virus Infection"
      ],
      "interventions": [
        {
          "name": "VLA1601",
          "type": "BIOLOGICAL"
        },
        {
          "name": "CpG 1018®",
          "type": "BIOLOGICAL"
        },
        {
          "name": "3M-052-AF",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Valneva Austria GmbH",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "ALL",
        "summary": "18 Years to 49 Years"
      },
      "enrollment_count": 150,
      "start_date": "2024-03-25",
      "completion_date": "2026-02-27",
      "has_results": false,
      "last_update_posted_date": "2026-03-09",
      "last_synced_at": "2026-09-23T06:49:53.395Z",
      "location_count": 4,
      "location_summary": "Chicago, Illinois • Sioux City, Iowa • Lincoln, Nebraska + 1 more",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Sioux City",
          "state": "Iowa"
        },
        {
          "city": "Lincoln",
          "state": "Nebraska"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06334393"
    },
    {
      "nct_id": "NCT03934736",
      "title": "HEPLISAV-B® in Adults With End-Stage Renal Disease (ESRD) Undergoing Hemodialysis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "End Stage Renal Disease on Hemodialysis (Diagnosis)"
      ],
      "interventions": [
        {
          "name": "HEPLISAV-B®",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dynavax Technologies Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 119,
      "start_date": "2019-04-22",
      "completion_date": "2021-09-15",
      "has_results": true,
      "last_update_posted_date": "2024-08-09",
      "last_synced_at": "2026-09-23T06:49:53.395Z",
      "location_count": 20,
      "location_summary": "Bloomfield, Connecticut • Middlebury, Connecticut • Hollywood, Florida + 17 more",
      "locations": [
        {
          "city": "Bloomfield",
          "state": "Connecticut"
        },
        {
          "city": "Middlebury",
          "state": "Connecticut"
        },
        {
          "city": "Hollywood",
          "state": "Florida"
        },
        {
          "city": "Ocala",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03934736"
    },
    {
      "nct_id": "NCT00426712",
      "title": "Safety of HEPLISAV™ Hepatitis B Virus Vaccine in End-stage Kidney Failure Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hepatitis B"
      ],
      "interventions": [
        {
          "name": "1018 ISS immunostimulatory oligonucleotide with HBV surface antigen",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Hepatitis B Vaccine (Recombinant)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Dynavax Technologies Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 42,
      "start_date": "2006-01",
      "completion_date": "2008-03",
      "has_results": false,
      "last_update_posted_date": "2019-03-20",
      "last_synced_at": "2026-09-23T06:49:53.395Z",
      "location_count": 4,
      "location_summary": "Costa Mesa, California • Brooklyn Center, Minnesota • Austin, Texas + 1 more",
      "locations": [
        {
          "city": "Costa Mesa",
          "state": "California"
        },
        {
          "city": "Brooklyn Center",
          "state": "Minnesota"
        },
        {
          "city": "Austin",
          "state": "Texas"
        },
        {
          "city": "Charlottesville",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00426712"
    }
  ]
}